title: Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management.
abstract: Intravascular metallic stents are increasingly used in the non-surgical management of coronary atherosclerosis. Despite intensive anticoagulation, subacute stent thrombosis, which usually has serious clinical consequences, and major haemorrhagic complications remain major problems after stent implantation. In addition, conventional management with anticoagulant therapy requires prolonged hospitalization. In a prospective multicentre study, we investigated the efficacy of a combination of two antiplatelet agents, ticlopidine 500 mg daily and aspirin 200 mg daily, without oral anticoagulation after stent implantation. Since November 1993, 529 consecutive patients, in whom 545 vessels were successfully stented with conventional (non-heparin coated) stents have been enrolled. Stenting was performed as a bailout procedure for failed angioplasty in 112 patients, for a suboptimal result after angioplasty in 314 patients, and electively in the remaining 103 patients. Coronary events related, or possibly related, to stent thrombosis occurred in 5.4% of patients stented as a bailout procedure and in 1.8% of patients stented for a suboptimal result. Serious bleeding complications occurred in 5.4% of patients stented as a bailout procedure and 1.5% of patients stented for a suboptimal result. Neither stent thrombosis nor serious bleeding complications were seen in patients stented electively. Ticlopidine therapy was discontinued in 1.9% of patients due to neutropenia (0.6%) or rash (1.3%). Mean hospital stay decreased from 6.16 +/- 2.14 days to 4.2 +/- 2.15 days during the study period. A combination of two antiplatelet agents can be employed in the vast majority of patients after coronary stent implantation. Subacute stent thrombosis rates and bleeding complications compare favourably with those reported using conventional therapy and the duration of hospitalization is reduced.
authors.affiliation: Service de Cardiologie B, Hopital Cardiologique, Lille, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Lablanche
authors.forename: E P
authors.initials: EP
authors.lastname: McFadden
authors.forename: J L
authors.initials: JL
authors.lastname: Bonnet
authors.forename: G
authors.initials: G
authors.lastname: Grollier
authors.forename: N
authors.initials: N
authors.lastname: Danchin
authors.forename: M
authors.initials: M
authors.lastname: Bedossa
authors.forename: C
authors.initials: C
authors.lastname: Leclercq
authors.forename: A
authors.initials: A
authors.lastname: Vahanian
authors.forename: C
authors.initials: C
authors.lastname: Bauters
authors.forename: E
authors.initials: E
authors.lastname: Van Belle
authors.forename: M E
authors.initials: ME
authors.lastname: Bertrand
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation* / Q000379:methods; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000628:therapy; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin